Navigation Links
Federal Members of Advisory Committee Block Vaccine-Autism Research, Defy Wishes of Its Own Scientists, Autism Community, and Congress
Date:1/16/2009

SafeMinds Withdraws Support for Autism Research Strategic Plan, Asks Daschle to Investigate.

WASHINGTON, Jan. 16 /PRNewswire-USNewswire/ -- In a highly unusual departure from procedure, government representatives to the Federal Interagency Autism Advisory Committee (IACC) voted this week against conducting studies on vaccine-autism research despite approval of the same studies at their prior meeting. The research was supported by numerous autism organizations and requested by IACC's scientific work groups and Congress. The maneuver to re-vote on the vaccine-autism studies was initiated by the IACC's representative from the CDC and pushed through by the IACC Chair, Dr. Tom Insel, Director of the National Institute of Mental Health of NIH.

Unlike most Federal advisory committees, the IACC is dominated by government representatives occupying 12 of the 18 seats. Of the 6 public members, 5 voted to retain the vaccine research at the meeting. The lone dissenting public member resigned from her organization, Autism Speaks, the night before the meeting. Autism Speaks has issued a statement condemning her vote.

The CDC, part of HHS along with NIH, has been criticized by parents citing failure to uphold vaccine safety. In a surprising moment of candor, Dr. Insel cited HHS conflicts of interests on vaccine-autism research due to the over 5,000 autism lawsuits pending against HHS. His comment supports the autism community's contention that those in charge of promoting vaccine use while assuring safety are fundamentally conflicted and should not investigate themselves.

IACC Member and SafeMinds Vice-President Lyn Redwood stated, "Revisiting objectives already approved did not appear on the meeting's agenda." She added, "Advocacy groups and legislators have been marginalized in this process."

Senators Enzi, Dodd, Kennedy and Santorum, as well as Representatives Barton and Smith made statements which are part of the Combating Autism Act of 2006 legislative history that research on vaccines and their components and autism should be implemented by the IACC.

Due to the IACC's actions, SafeMinds has withdrawn its support of the IACC Strategic Plan for Autism Research and requests that incoming HHS Secretary Daschle investigate the IACC's action and reconstitute the committee, including removal of NIMH as its lead agency.

SafeMinds is a private nonprofit organization that investigates and raises awareness of the risks to children of exposure to mercury from the environment and medical products, including thimerosal in vaccines.


'/>"/>
SOURCE SafeMinds
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices
2. U.S. House Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes
3. American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness
4. Zumas Rescue Ranch becomes a Federal 501C3
5. Clock Ticking for Millions of Federal Employees Hoping to Avoid Blue Cross/Blue Shield Benefits Cut
6. Riverside County Registered Nurses File a Lawsuit to Stop Countys Violation of Federal Law
7. Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA)
8. National Patient Advocate Foundation (NPAF) Announces New Executive Vice President of Federal Legislative Affairs
9. ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration
10. Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, Were Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged
11. Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: